Quarterly report pursuant to Section 13 or 15(d)

Note 12 - Segment Information - Financial Information Relating to Reportable Segments (Details)

v3.19.1
Note 12 - Segment Information - Financial Information Relating to Reportable Segments (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Mar. 31, 2019
Mar. 31, 2018
Mar. 31, 2019
Mar. 31, 2018
Net sales $ 184,861 $ 163,973 $ 522,341 $ 462,739
Operating income 44,090 43,084 103,455 93,263
Costs recognized on sale of acquired inventory     (2,804) (2,013)
Amortization of acquisition related intangible assets     (43,797)  
Corporate general, selling, and administrative expenses (64,968) (53,285) (195,622) (175,349)
Operating Segments [Member]        
Operating income 65,835 63,462 180,882 173,056
Operating Segments [Member] | Protein Sciences [Member]        
Net sales 137,935 123,187 399,787 348,442
Operating income 62,256 53,813 175,821 150,240
Operating Segments [Member] | Diagnostics and Genomics [Member]        
Net sales 47,134 40,929 123,144 114,604
Operating income 3,579 9,649 5,061 22,816
Intersegment Eliminations [Member]        
Net sales (208) (143) (590) (307)
Segment Reconciling Items [Member]        
Costs recognized on sale of acquired inventory (935) (1,431) (2,804) (2,013)
Amortization of acquisition related intangible assets (14,400) (11,872) (43,678) (34,547)
Acquisition related expenses (1,312) (2,973) (23,994)
Stock based compensation (5,725) (4,748) (24,151) (13,587)
Corporate, Non-Segment [Member]        
Corporate general, selling, and administrative expenses $ (685) $ (1,015) $ (3,821) $ (5,652)